경피증 치료제 시장 규모, 점유율 및 성장 분석 : 약제 클래스별, 적응증별, 투여 경로별, 유통 채널별, 최종사용자별, 치료법별, 지역별 - 업계 예측(2026-2033년)

Global Scleroderma Therapeutics Market size was valued at USD 2.7 Billion in 2024 and is poised to grow from USD 2.85 Billion in 2025 to USD 4.37 Billion by 2033, growing at a CAGR of 5.5% during the forecast period (2026-2033).

The scleroderma therapeutics market is undergoing significant transformation driven by advancements in molecular understanding and targeted drug development. This previously neglected area is now rich with clinical innovation, focusing on treatments for systemic sclerosis and localized scleroderma, which include immunomodulators, antifibrotics, biologics, and supportive therapies. With recent discoveries linking key biological factors to disease pathogenesis, therapeutic trials for drugs like nintedanib and tocilizumab have shifted from research to clinical application, altering treatment approaches. The establishment of orphan designations and acceptance of surrogate endpoints by regulatory agencies have incentivized manufacturers, leading to increased investment and expanded clinical programs. This growth allows for greater therapy accessibility, as evidenced by the wider adoption of nintedanib in treating fibrotic lung disease, while also fostering pipeline diversification among companies.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Scleroderma Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Scleroderma Therapeutics Market Segments Analysis

Global scleroderma therapeutics market is segmented by drug class, indication, route of administration, distribution channel, end-user, therapy type and region. Based on drug class, the market is segmented into Immunosuppressants, Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase-5 (PDE-5) Inhibitors, Antifibrotic Agents, Biologics & Monoclonal Antibodies and Others. Based on indication, the market is segmented into Systemic Scleroderma and Localized Scleroderma. Based on route of administration, the market is segmented into Oral, Injectable and Topical. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on end-user, the market is segmented into Hospitals, Specialty Clinics and Home Care. Based on therapy type, the market is segmented into Symptomatic Treatment, Disease-Modifying Therapies and Combination Therapies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Scleroderma Therapeutics Market

The Global Scleroderma Therapeutics market is driven by the emergence of targeted biologic treatments that offer more precise strategies for addressing the diverse manifestations of scleroderma. This advancement fosters increased investment and interest in clinical research, resulting in a wider array of treatment options for healthcare providers and patients. The focus on disease-modifying therapies enhances collaboration across the research community, instills greater confidence among prescribers, and encourages the development of therapies that directly address the underlying disease mechanisms. Additionally, the expansion of therapeutic options facilitates stronger regulatory engagement and commercial partnerships, ultimately accelerating the timeline for bringing new treatments into clinical use.

Restraints in the Global Scleroderma Therapeutics Market

The global market for scleroderma therapeutics faces significant challenges primarily due to the high costs associated with developing new therapies. The financial burden of extensive clinical programs and the need for specialized trial designs puts immense pressure on developers, which can hinder the advancement of innovative treatments toward commercialization. When budgets are limited, companies often prioritize candidates with wider market appeal, thereby neglecting rarer disease indications. Additionally, financial constraints impact pricing strategies and negotiations with payers, which in turn can affect the commercial viability of therapeutic options. These economic factors contribute to a slower pace of innovation and limit the variety of treatments available in clinical practice.

Market Trends of the Global Scleroderma Therapeutics Market

The Global Scleroderma Therapeutics market is witnessing a significant shift towards precision medicine, with an increasing focus on biomarker-driven approaches and patient stratification. This trend is driving the development of individualized treatments that address the varied manifestations of scleroderma. Collaborations between pharmaceutical companies and diagnostics firms are establishing targeted clinical pathways, enhancing adaptive care models. Payers and healthcare providers are recognizing the value of therapies tied to predictive diagnostics, facilitating favorable reimbursement opportunities. Furthermore, commercial strategies are increasingly centered on patient-centric outcomes, promoting long-term adherence and improved quality of life through precise therapeutic selection and monitoring techniques.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Value Chain Analysis
• Case Studies
• Technology Assessment
• Customer & Buying Criteria Analysis
• Pipeline Analysis
• Disease Epidemiology

Global Scleroderma Therapeutics Market Size by Drug Class & CAGR (2026-2033)

• Market Overview
• Immunosuppressants
• Endothelin Receptor Antagonists
• Prostacyclin Analogs
• Phosphodiesterase-5 (PDE-5) Inhibitors
• Antifibrotic Agents
• Biologics & Monoclonal Antibodies
• Others

Global Scleroderma Therapeutics Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Systemic Scleroderma
• Localized Scleroderma

Global Scleroderma Therapeutics Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Injectable
• Topical

Global Scleroderma Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Scleroderma Therapeutics Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Specialty Clinics
• Home Care

Global Scleroderma Therapeutics Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• Symptomatic Treatment
• Disease-Modifying Therapies
• Combination Therapies

Global Scleroderma Therapeutics Market Size & CAGR (2026-2033)

• North America (Drug Class, Indication, Route of Administration, Distribution Channel, End-User, Therapy Type)
  • US
  • Canada
• Europe (Drug Class, Indication, Route of Administration, Distribution Channel, End-User, Therapy Type)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Indication, Route of Administration, Distribution Channel, End-User, Therapy Type)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Indication, Route of Administration, Distribution Channel, End-User, Therapy Type)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Indication, Route of Administration, Distribution Channel, End-User, Therapy Type)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• F. Hoffmann-La Roche Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biogen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• UCB S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Horizon Therapeutics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kadmon Holdings
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Corbus Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Galapagos NV
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations